Concepedia

Author

Sonia I. Skarlatos

National Institutes of Health

Also Known As

SONIA I. SKARLATOS, Sonia I Skarlatos, Sonia I. Skarlatos, Sonia Skarlatos

39

Publications

2.6K

Citations

17

H-Index

71

Concepts

All Affiliations

National Institutes of HealthNational Heart Lung and Blood InstituteThe University of Texas Health Science Center at HoustonUniversity of FloridaMinneapolis Heart Institute Foundation
SI

About

Sonia I. Skarlatos is an author at National Institutes of Health specializing in medicine, cardiology, and cardiovascular disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

14

695

2

Engineering

2

2

35

3

Public Health

2

2

91

4

Health Sciences

1

1

42

5

Allergy

1

1

43

Sonia I. Skarlatos

×

20

Publications

1.9K

Citations

15

H-Index

YearCitations

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure

Emerson C. Perin, James T. Willerson, Carl J. Pepine,

JAMA

2012

454

Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction

Jay H. Traverse, Timothy D. Henry, Carl J. Pepine,

JAMA

2012

386

Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions

Santica M. Marcovina, Marlys L. Koschinsky, John J. Albers,

Clinical Chemistry

2003

280

Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus

Peter Libby, David M. Nathan, Kristin Abraham,

Circulation

2005

266

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction

Jay H. Traverse, Timothy D. Henry, Douglas Vaughn,

American Heart Journal

2009

77

The release of thromboxane A2 and prostacyclin following experimental acute pulmonary embolism

William C. Reeves, Laurence M. Demers, Mary A. Wood,

Prostaglandins Leukotrienes and Medicine

1983

63

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Jay H. Traverse, Timothy D. Henry, Douglas E. Vaughan,

PubMed

2010

56

Phase II Clinical Research Design in Cardiology

Joshua M. Hare, Roberto Bolli, John P. Cooke,

Circulation

2013

46

Accumulation of HDL Apolipoproteins Accompanies Abnormal Cholesterol Accumulation in Schnyder's Corneal Dystrophy

Paulette M. Gaynor, Weiyang Zhang, Jayne S. Weiss,

Arteriosclerosis Thrombosis and Vascular Biology

1996

43

Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design

James T. Willerson, Emerson C. Perin, Stephen G. Ellis,

American Heart Journal

2010

42

Page 1